Navigation Links
Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Date:12/8/2011

HAYWARD, Calif., Dec. 8, 2011 /PRNewswire/ -- Metabolex today announced positive results from its clinical study of arhalofenate in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid (sUA). In the US, the goal of treatment is to reduce sUA levels to below 6 mg/dL. However, patients with severe tophaceous gout would benefit from reducing their sUA values below 5 or even 4 mg/dL because this would result in more rapid dissolution of their UA crystal deposits. Most patients treated with currently marketed xanthine oxidase inhibitors (allopurinol or febuxostat) alone do not reach these goals. Arhalofenate, Metabolex's lead product candidate for the treatment of hyperuricemia and gout, is a uricosuric agent that could provide additional sUA lowering when used in combination with xanthine oxidase inhibitors and be a treatment option for patients with tophaceous gout.

Clinical Study of Combination of Arhalofenate and Febuxostat

This study was an open label clinical pharmacology study on a single cohort of 11 gout patients with sUA levels of at least 8 mg/dL (mean of 9.1 mg/dL). The primary goal of the study was to assess the response rate (percentage of patients reaching goal) for the sUA targets of 5 and 4 mg/dL when treated in combination with the highest dose (80 mg) of febuxostat approved in the US and two doses (400 and 600 mg) of arhalofenate. The patients were either treatment naive or had discontinued uric acid lowering therapies for a period prior to entering the study. All patients received colchicine throughout the study for flare prophylaxis. After a two week run-in period for sUA stabilization, all 11 patients received febuxostat (80 mg) for one week. Subsequently, patients were administered 400 mg of arhalofenate for two weeks followed by up-titration of arhalo
'/>"/>

SOURCE Metabolex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
2. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
3. Metabolex Announces Election of Kurt von Emster to Board of Directors
4. Metabolex Initiates Phase 2 Trial of Arhalofenate
5. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
6. Metabolex Gout Program Recognized in Windhovers Top 10 Most Interesting Projects to Watch
7. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
8. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
9. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
10. Anesiva Announces Second Quarter 2008 Financial Results and Update
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  Emdeon Inc. today announced ... agreement to acquire Altegra Health, a national ... combine data aggregation and analytics with unique ... actionable insights and improved management for value-based ... risk adjustment and quality analytics and Emdeon,s ...
(Date:7/6/2015)... 29, 2015 Research ... addition of the "Biotechnology for the Non-Biotechnologist" ... for the Non-Biotechnologist, ideal for non-Scientists and Scientists ... and potential of biotechnology. Ideal for ... theory, principles, techniques, and potential of biotechnology ...
(Date:7/6/2015)... a leading Regulatory Service provider, today announced that it has opened a ... Colombia . Navitas, expansion into Latin America ... , the third largest economy in Latin America ... http://photos.prnewswire.com/prnh/20150703/228239LOGO ... Navitas regulatory professionals in close to or the same time zone and ...
(Date:7/5/2015)... ... ... For many years, metal-on-quartz filters were the industry standard for the calibration of ... 4000-7000, a Perkin Elmer 800-1100 or a Shimadzu 3600-3700, these filters would work like ... SRM-2031 series going back for many years. Unfortunately, these standards remained unusable for the ...
Breaking Biology Technology:Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3
... 9 Kendle (Nasdaq: KNDL ), ... announced Chief Operating Officer Christopher Bergen will participate ... March 10 as well as the Raymond James ... http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ) Barclays ...
... Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged ... announced that the U.S. Food and Drug Administration (FDA) ... Adhesion Barrier for use in pediatric cardiac surgery patients. ... over the surface of the heart at the conclusion ...
... Alliance, the leading management consulting firm specializing in ... Joe Dillon has joined its Business Development Practice. ... Business Development Practice to help pharmaceutical and biotech ... related to in- and out-licensing, opportunity assessment, and ...
Cached Biology Technology:Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 2FDA Approves SyntheMed's REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery 3Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 2Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 3
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... A recently released scientific paper authored by San ... leading causes of death of the endangered California condor ... being the primary factor in juvenile and adult birds. ... California condors at all release sitesCalifornia, Arizona and Baja, ...
... new way to create electromagnetic Terahertz (THz) waves or T-rays ... the study, published recently in the journal Nature Photonics ... T-rays could be used to make better medical scanning gadgets ... ,tricorder, scanner used in Star Trek. In the study, ...
... Jan. 20, 2012   Cell Therapeutics, Inc. ("CTI") (NASDAQ ... the European Medicines Agency,s ("EMA") Committee for Medicinal Products ... opinion on CTI,s Marketing Authorization Application ("MAA") for Pixuvri ... work with the CHMP on the Summary of Product ...
Cached Biology News:Scientific paper shows California condor still threatened by human activities 2T-rays technology could help develop Star Trek-style hand-held medical scanners 2T-rays technology could help develop Star Trek-style hand-held medical scanners 3Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 2Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 3
... is the first all-inclusive collection of key ... Expression System. Methods developed by the leaders ... step-by-step protocols. This book will guide you ... strain construction and analysis, to production of ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
Biology Products: